All webinar times are in Eastern Time except where noted. Convert to your time zone.
The majority of celiac disease (CD) affected patients are a/hypo symptomatic and undiagnosed, and are at risk of preventable complications. Therefore, early and correct diagnosis is highly recommended. Multiple diagnostic antibodies are available, the most frequently used is IgA-tissue transglutaminase (tTg). It may yield false results and, alone, does not address IgA deficiency.
Recently, a new generation of anti neo-epitope tTg IgG+IgA (tTg-neo, check) has become available. It is highly sensitive and specific, covers IgA deficient CD patients, reflects intestinal injury and has predictive potential in celiac disease diagnosis. It is considered as the prime serological marker for CD diagnosis.
WHAT YOU WILL LEARN
- Celiac disease is a small intestine inflammatory autoimmune disorder in genetically susceptible individuals, triggered by digestion of prolamins.
- The serological markers for celiac disease include anti-endomysial, anti deamidated gliadin and the anti-transglutaminase antibodies
- The anti neo-epitope transglutaminase antibodies are created against the transglutaminase cross-linked gliadin peptides and represent a new generation of celiac disease diagnostic markers
- The advantages of the neo-epitope transglutaminase on the anti-transglutaminase antibodies are: better diagnostic performances, higher reflection of intestinal damage, better predictability in early age, more diverse epitopes and less false positivity. Nowadays, it is the prime diagnostic antibody for celiac disease.
Aaron Lerner, MD, MHA
Carmel Medical Center
B. Rappaport School of Medicine
Technion Israel Institute of Technology